Symbols / VRDN
VRDN Chart
About
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.76B |
| Enterprise Value | 2.48B | Income | -245.32M | Sales | 70.79M |
| Book/sh | 3.82 | Cash/sh | 5.14 | Dividend Yield | — |
| Payout | 0.00% | Employees | 143 | IPO | — |
| P/E | — | Forward P/E | -7.92 | PEG | — |
| P/S | 39.02 | P/B | 7.58 | P/C | — |
| EV/EBITDA | -7.66 | EV/Sales | 35.09 | Quick Ratio | 11.06 |
| Current Ratio | 11.28 | Debt/Eq | 4.81 | LT Debt/Eq | — |
| EPS (ttm) | -3.03 | EPS next Y | -3.66 | EPS Growth | — |
| Revenue Growth | 819.58% | Earnings | 2026-02-26 | ROA | -30.08% |
| ROE | -49.89% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -56.70% | Profit Margin | 0.00% | Shs Outstand | 95.37M |
| Shs Float | 95.41M | Short Float | 8.63% | Short Ratio | 5.34 |
| Short Interest | — | 52W High | 34.29 | 52W Low | 9.90 |
| Beta | 0.98 | Avg Volume | 1.51M | Volume | 1.02M |
| Target Price | $42.06 | Recom | Strong_buy | Prev Close | $29.40 |
| Price | $28.94 | Change | -1.56% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$42.06
Mean price target
2. Current target
$28.94
Latest analyst target
3. DCF / Fair value
$-41.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.94
Low
$29.00
High
$50.00
Mean
$42.06
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-04 | reit | Needham | Buy → Buy | $42 |
| 2026-02-03 | main | Wells Fargo | Equal-Weight → Equal-Weight | $29 |
| 2026-01-08 | main | Truist Securities | Buy → Buy | $40 |
| 2026-01-07 | init | UBS | — → Buy | $50 |
| 2025-12-23 | main | Needham | Buy → Buy | $42 |
| 2025-12-10 | main | Wedbush | Outperform → Outperform | $47 |
| 2025-12-03 | init | William Blair | — → Outperform | — |
| 2025-11-24 | init | Truist Securities | — → Buy | $41 |
| 2025-11-06 | main | RBC Capital | Outperform → Outperform | $45 |
| 2025-11-04 | reit | BTIG | Buy → Buy | $61 |
| 2025-10-21 | main | Oppenheimer | Outperform → Outperform | $36 |
| 2025-08-07 | main | Goldman Sachs | Buy → Buy | $30 |
| 2025-08-07 | main | RBC Capital | Outperform → Outperform | $41 |
| 2025-08-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $26 |
| 2025-08-07 | main | Oppenheimer | Outperform → Outperform | $32 |
| 2025-08-06 | main | Needham | Buy → Buy | $34 |
| 2025-05-20 | reit | Needham | Buy → Buy | $36 |
| 2025-05-07 | main | RBC Capital | Outperform → Outperform | $45 |
| 2025-05-07 | main | Goldman Sachs | Buy → Buy | $27 |
| 2025-05-07 | main | JMP Securities | Market Outperform → Market Outperform | $38 |
- Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - The Motley Fool Mon, 23 Feb 2026 15
- Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - The Globe and Mail Mon, 23 Feb 2026 19
- Viridian Therapeutics, Inc. (VRDN) Stock Analysis: A 50.75% Upside Potential In Biotech - DirectorsTalk Interviews ue, 17 Feb 2026 14
- Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance Wed, 05 Nov 2025 08
- Goldman Sachs reiterates Buy rating on Viridian Therapeutic stock - Investing.com hu, 18 Dec 2025 08
- How Viridian Therapeutics Inc. (VRDN) Affects Rotational Strategy Timing - Stock Traders Daily Fri, 06 Feb 2026 08
- Viridian Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis Sun, 21 Dec 2025 08
- Viridian (NASDAQ: VRDN) expects 60-day FDA decision on veligrotug BLA for TED - Stock Titan Mon, 03 Nov 2025 08
- $VRDN stock is up 14% today. Here's what we see in our data. - Quiver Quantitative hu, 06 Nov 2025 08
- Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire ue, 21 Oct 2025 07
- Viridian Therapeutics (VRDN) Receives Updated Analyst Rating fro - GuruFocus ue, 03 Feb 2026 08
- Viridian Therapeutics Is Ready For An Eventful 2026 (NASDAQ:VRDN) - Seeking Alpha hu, 06 Nov 2025 08
- Viridian Therapeutics, Inc. (VRDN) Stock Surges on Dec. 15, 2025: Latest News, Analyst Forecasts, and 2026 Catalysts - TechStock² Mon, 15 Dec 2025 08
- Viridian Therapeutics (VRDN): Assessing Valuation Following $300 Million Royalty Financing for Thyroid Eye Disease Launch - Yahoo Finance ue, 21 Oct 2025 07
- Viridian Therapeutics, Inc. (VRDN) Stock Analysis: Unveiling an 81,958% Revenue Growth Opportunity - DirectorsTalk Interviews ue, 16 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2272 | 70796 | — | Sale at price 31.16 per share. | TOUSIGNANT JENNIFER | Officer | — | 2025-12-31 00:00:00 | D |
| 1 | 454545 | 9999990 | — | Purchase at price 22.00 per share. | FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-23 00:00:00 | I |
| 2 | 14100 | 166355 | — | Conversion of Exercise of derivative security at price 7.80 - 12.31 per share. | FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-10 00:00:00 | I |
| 3 | 5000 | 117050 | — | Purchase at price 23.41 per share. | BEETHAM THOMAS W | Chief Operating Officer | — | 2024-09-27 00:00:00 | D |
| 4 | 21400 | 499262 | — | Purchase at price 23.33 per share. | MAHONEY STEPHEN F | Chief Executive Officer | — | 2024-09-27 00:00:00 | D |
| 5 | 1600000 | 30000000 | — | Purchase at price 18.75 per share. | FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2024-09-13 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -266.36M | -235.37M | -129.13M | -79.29M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -269.95M | -237.73M | -129.87M | -79.41M |
| ReconciledDepreciation | 540.00K | 522.00K | 255.00K | 120.00K |
| EBITDA | -266.36M | -235.37M | -129.13M | -79.29M |
| EBIT | -266.90M | -235.89M | -129.39M | -79.41M |
| NetInterestIncome | 29.09M | 16.72M | 4.43M | 315.00K |
| InterestExpense | 3.05M | 1.85M | 486.00K | 3.00K |
| InterestIncome | 32.13M | 18.56M | 4.92M | 318.00K |
| NormalizedIncome | -269.95M | -237.73M | -129.87M | -79.41M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -269.95M | -237.73M | -129.87M | -79.41M |
| TotalExpenses | 299.34M | 254.76M | 136.08M | 82.69M |
| TotalOperatingIncomeAsReported | -299.04M | -254.45M | -134.30M | -79.73M |
| DilutedAverageShares | 67.89M | 44.76M | 32.09M | 11.92M |
| BasicAverageShares | 67.89M | 44.76M | 32.09M | 11.92M |
| DilutedEPS | -3.07 | -5.31 | -4.05 | -6.66 |
| BasicEPS | -3.07 | -5.31 | -4.05 | -6.66 |
| DilutedNIAvailtoComStockholders | -269.95M | -237.73M | -129.87M | -79.41M |
| NetIncomeCommonStockholders | -269.95M | -237.73M | -129.87M | -79.41M |
| NetIncome | -269.95M | -237.73M | -129.87M | -79.41M |
| NetIncomeIncludingNoncontrollingInterests | -269.95M | -237.73M | -129.87M | -79.41M |
| NetIncomeContinuousOperations | -269.95M | -237.73M | -129.87M | -79.41M |
| PretaxIncome | -269.95M | -237.73M | -129.87M | -79.41M |
| SpecialIncomeCharges | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 29.09M | 16.72M | 4.43M | 315.00K |
| InterestExpenseNonOperating | 3.05M | 1.85M | 486.00K | 3.00K |
| InterestIncomeNonOperating | 32.13M | 18.56M | 4.92M | 318.00K |
| OperatingIncome | -299.04M | -254.45M | -134.30M | -79.73M |
| OperatingExpense | 299.34M | 254.76M | 136.08M | 82.69M |
| ResearchAndDevelopment | 238.25M | 159.76M | 100.89M | 56.89M |
| SellingGeneralAndAdministration | 61.08M | 95.00M | 35.18M | 25.80M |
| GeneralAndAdministrativeExpense | 61.08M | 95.00M | 35.18M | 25.80M |
| OtherGandA | 61.08M | 95.00M | 35.18M | 25.80M |
| TotalRevenue | 302.00K | 314.00K | 1.77M | 2.96M |
| OperatingRevenue | 302.00K | 314.00K | 1.77M | 2.96M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 80.99M | 53.99M | 41.31M | 23.92M |
| ShareIssued | 80.99M | 53.99M | 41.31M | 23.92M |
| TotalDebt | 21.09M | 21.05M | 5.26M | 520.00K |
| TangibleBookValue | 482.75M | 235.51M | 252.92M | 53.88M |
| InvestedCapital | 503.34M | 255.71M | 257.56M | 53.88M |
| WorkingCapital | 690.59M | 459.84M | 397.82M | 186.53M |
| NetTangibleAssets | 671.64M | 442.02M | 395.06M | 187.72M |
| CapitalLeaseObligations | 513.00K | 843.00K | 613.00K | 520.00K |
| CommonStockEquity | 482.75M | 235.51M | 252.92M | 53.88M |
| PreferredStockEquity | 188.88M | 206.52M | 142.15M | 133.83M |
| TotalCapitalization | 692.22M | 462.23M | 399.71M | 187.72M |
| TotalEquityGrossMinorityInterest | 671.64M | 442.02M | 395.06M | 187.72M |
| StockholdersEquity | 671.64M | 442.02M | 395.06M | 187.72M |
| GainsLossesNotAffectingRetainedEarnings | -10.00K | 338.00K | -390.00K | -157.00K |
| OtherEquityAdjustments | -10.00K | 338.00K | -390.00K | -157.00K |
| RetainedEarnings | -995.86M | -725.91M | -488.17M | -358.30M |
| AdditionalPaidInCapital | 1.48B | 960.54M | 741.07M | 412.10M |
| CapitalStock | 189.69M | 207.06M | 142.56M | 134.07M |
| CommonStock | 810.00K | 540.00K | 414.00K | 239.00K |
| PreferredStock | 188.88M | 206.52M | 142.15M | 133.83M |
| TotalLiabilitiesNetMinorityInterest | 70.76M | 48.40M | 40.03M | 15.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 22.89M | 21.77M | 6.68M | 2.36M |
| OtherNonCurrentLiabilities | 2.02M | 989.00K | 1.17M | 1.21M |
| DuetoRelatedPartiesNonCurrent | 1.15M | |||
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| NonCurrentDeferredLiabilities | 284.00K | 573.00K | 861.00K | 1.15M |
| NonCurrentDeferredRevenue | 284.00K | 573.00K | 861.00K | 1.15M |
| LongTermDebtAndCapitalLeaseObligation | 20.58M | 20.20M | 4.64M | |
| LongTermDebt | 20.58M | 20.20M | 4.64M | |
| CurrentLiabilities | 47.87M | 26.64M | 33.35M | 13.64M |
| OtherCurrentLiabilities | 100.00K | 100.00K | 100.00K | 100.00K |
| CurrentDeferredLiabilities | 288.00K | 288.00K | 288.00K | 289.00K |
| CurrentDeferredRevenue | 288.00K | 288.00K | 288.00K | 289.00K |
| CurrentDebtAndCapitalLeaseObligation | 513.00K | 843.00K | 613.00K | 520.00K |
| CurrentCapitalLeaseObligation | 513.00K | 843.00K | 613.00K | 520.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 10.64M | 10.51M | 4.77M | 3.65M |
| PayablesAndAccruedExpenses | 36.34M | 14.89M | 27.58M | 9.07M |
| CurrentAccruedExpenses | 34.19M | 12.65M | 13.34M | 6.75M |
| InterestPayable | 154.00K | 154.00K | 39.00K | |
| Payables | 2.14M | 2.24M | 14.23M | 2.33M |
| AccountsPayable | 2.14M | 2.24M | 14.23M | 2.33M |
| TotalAssets | 742.40M | 490.42M | 435.09M | 203.71M |
| TotalNonCurrentAssets | 3.94M | 3.95M | 3.92M | 3.55M |
| OtherNonCurrentAssets | 501.00K | 604.00K | 982.00K | 1.49M |
| NetPPE | 3.44M | 3.34M | 2.94M | 2.06M |
| AccumulatedDepreciation | -1.27M | -1.05M | -2.00M | -1.78M |
| GrossPPE | 4.71M | 4.39M | 4.94M | 3.83M |
| Leases | 254.00K | 670.00K | 1.11M | 749.00K |
| OtherProperties | 3.35M | 2.81M | 2.77M | 2.46M |
| MachineryFurnitureEquipment | 1.11M | 906.00K | 1.06M | 627.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 738.46M | 486.48M | 431.17M | 200.16M |
| OtherCurrentAssets | 20.88M | 9.01M | 6.52M | 2.75M |
| PrepaidAssets | 2.75M | |||
| Receivables | 0.00 | 102.00K | 102.00K | 451.00K |
| OtherReceivables | 102.00K | 102.00K | 451.00K | |
| CashCashEquivalentsAndShortTermInvestments | 717.58M | 477.37M | 424.55M | 196.97M |
| OtherShortTermInvestments | 617.99M | 374.54M | 268.97M | 154.67M |
| CashAndCashEquivalents | 99.59M | 102.83M | 155.58M | 42.30M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -232.83M | -185.07M | -94.64M | -54.92M |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | 15.00M | 5.00M | 0.00 |
| IssuanceOfCapitalStock | 478.66M | 201.26M | 335.87M | 131.20M |
| CapitalExpenditure | -511.00K | -898.00K | -797.00K | -338.00K |
| InterestPaidSupplementalData | 1.82M | 886.00K | 293.00K | 0.00 |
| EndCashPosition | 99.59M | 102.83M | 155.58M | 42.30M |
| BeginningCashPosition | 102.83M | 155.58M | 42.30M | 45.90M |
| ChangesInCash | -3.23M | -52.75M | 113.28M | -3.60M |
| FinancingCashFlow | 457.74M | 225.67M | 322.24M | 125.28M |
| CashFlowFromContinuingFinancingActivities | 457.74M | 225.67M | 322.24M | 125.28M |
| NetOtherFinancingCharges | -26.94M | -12.31M | -22.51M | -8.28M |
| ProceedsFromStockOptionExercised | 6.02M | 21.72M | 3.88M | 2.35M |
| NetPreferredStockIssuance | 25.00M | 76.19M | 44.00M | 16.96M |
| PreferredStockIssuance | 25.00M | 76.19M | 44.00M | 16.96M |
| NetCommonStockIssuance | 453.66M | 125.07M | 291.87M | 114.24M |
| CommonStockIssuance | 453.66M | 125.07M | 291.87M | 114.24M |
| NetIssuancePaymentsOfDebt | 0.00 | 15.00M | 5.00M | 0.00 |
| NetLongTermDebtIssuance | 0.00 | 15.00M | 5.00M | 0.00 |
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | 15.00M | 5.00M | 0.00 |
| InvestingCashFlow | -228.65M | -94.25M | -115.13M | -74.29M |
| CashFlowFromContinuingInvestingActivities | -228.65M | -94.25M | -115.13M | -74.29M |
| NetInvestmentPurchaseAndSale | -228.14M | -93.35M | -114.33M | -74.03M |
| SaleOfInvestment | 466.93M | 314.53M | 108.94M | 114.40M |
| PurchaseOfInvestment | -695.07M | -407.88M | -223.26M | -188.43M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -511.00K | -898.00K | -797.00K | -259.00K |
| SaleOfPPE | 0.00 | 0.00 | 79.00K | |
| PurchaseOfPPE | -511.00K | -898.00K | -797.00K | -338.00K |
| OperatingCashFlow | -232.32M | -184.17M | -93.84M | -54.58M |
| CashFlowFromContinuingOperatingActivities | -232.32M | -184.17M | -93.84M | -54.58M |
| ChangeInWorkingCapital | 9.60M | -9.43M | 15.96M | 1.72M |
| ChangeInOtherWorkingCapital | -288.00K | -288.00K | -288.00K | 636.00K |
| ChangeInPayablesAndAccruedExpense | 21.55M | -7.03M | 19.24M | 3.04M |
| ChangeInAccruedExpense | 21.62M | 5.01M | 7.72M | 1.38M |
| ChangeInPayable | -73.00K | -12.04M | 11.52M | 1.66M |
| ChangeInAccountPayable | -73.00K | -12.04M | 11.52M | 1.66M |
| ChangeInPrepaidAssets | -11.77M | -2.11M | -3.34M | -1.50M |
| ChangeInReceivables | 102.00K | 0.00 | 349.00K | -451.00K |
| OtherNonCashItems | 548.00K | 6.60M | 264.00K | 7.49M |
| StockBasedCompensation | 42.15M | 67.17M | 19.77M | 14.46M |
| AmortizationOfSecurities | -15.65M | -11.49M | -210.00K | 965.00K |
| DepreciationAmortizationDepletion | 540.00K | 522.00K | 255.00K | 120.00K |
| DepreciationAndAmortization | 540.00K | 522.00K | 255.00K | 120.00K |
| OperatingGainsLosses | 449.00K | 182.00K | 73.00K | |
| GainLossOnInvestmentSecurities | -4.00K | |||
| GainLossOnSaleOfPPE | 449.00K | 1.00K | 0.00 | 77.00K |
| NetIncomeFromContinuingOperations | -269.95M | -237.73M | -129.87M | -79.41M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VRDN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|